SLE diagnosis and treatment: When early is early

Autoimmunity Reviews

Volumn 10, Issue 1, 2010, Pages 55-60

  Doria, Andrea ^a   Zen, Margherita ^a   Canova, Mariagrazia ^a   Bettio, Silvano ^a   Bassi, Nicola ^a   Nalotto, Linda ^a   Rampudda, Mariaelisa ^a   Ghirardello, Anna ^a   Iaccarino, Luca ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; B CELL ACTIVATING FACTOR; COLECALCIFEROL; COMPLEMENT COMPONENT C1Q ANTIBODY; EDRATIDE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN ANTIBODY; RIBOSOME PROTEIN P ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION;

HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; TIME FACTORS;

EID: 78149359043     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.08.014     Document Type: Review

References (40)

1. Wallace D.J., Podell T., Weiner J., Klinenberg J.R., Forouzesh S., Dubois E.L. Systemic lupus erythematosus-survival patterns. Experience with 609 patients. JAMA 1981, 245(9):934-938.
2. Pistiner M., Wallace D.J., Nessim S., Metzger A.L., Klinenberg J.R. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991, 21(1):55-64.
3. Doria A., Iaccarino L., Ghirardello A., Zampieri S., Arienti S., Sarzi-Puttini P., et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006, 119:1497-1499.
4. Doria A., Rinaldi S., Ermani M., Salaffi F., Iaccarino L., Ghirardello A., et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological, and psychological determinants. Rheumatology 2004, 43:1580-1586.
5. Doria A., Briani C. Lupus: improving long-term prognosis. Lupus 2008, 17:166-170.
6. Doria A., Arienti S., Rampudda M., Canova M., Tonon M., Sarzi-Puttini P. Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008, 7:192-197.
7. Doria A., Canova M., Tonon M., Zen M., Rampudda E., Bassi N., et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008, 8(1):24-28.
8. Doria A., Zampieri S., Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev 2008, 8(2):89-91.
9. Ghirardello A., Doria A., Zampieri S., Tarricone E., Tozzoli R., Villalta D., et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun 2004, 22(3):235-240.
10. Zabaleta-Lanz M.E., Muñoz L.E., Tapanes F.J., Vargas-Arenas R.E., Daboin I., Barrios Y., et al. Further description of early clinically silent lupus nephritis. Lupus 2006, 15(12):845-851.
11. Norby G.E., Strøm E.H., Midtvedt K., Hartmann A., Gilboe I.M., Leivestad T., et al. Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study. Ann Rheum Dis 2010, 69(8):1484-1487.
12. Doria A., Mosca M., Gambari P.F., Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated or both?. J Rheumatol 2005, 32:213-215.
13. Sorani M.D., Ortmann W.A., Bierwagen E.P., Behrens T.W. Clinical and biological data integration for biomarker discovery. Drug Discov Today Jun 14 2010, (Epub ahead of print).
14. Liu C.C., Ahearn J.M. The search for lupus biomarkers. Best Pract Res Clin Rheumatol 2009, 23(4):507-523.
15. Ghirardello A., Caponi L., Franceschini F., Zampieri S., Gambari P.F., Doria A. Diagnostic tests for antiribosomal P protein antibodies: a comparative evaluation of immunoblotting and ELISA assays. J Autoimmun 2002, 19:71-77.
16. Briani C., Lucchetta M., Ghirardello A., Toffanin E., Zampieri S., Ruggero S., et al. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun 2009, 32(2):79-84.
17. Ghirardello A., Briani C., Lucchetta M., Doria A. Anti-ribosomal P protein antibodies and neuropsychiatric systemic lupus erythematosus: cross-sectional vs. prospective studies. Lupus 2010, 19(6):771-773.
18. Bigler C., Schaller M., Perahud I., Osthoff M., Trendelenburg M. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol 2009, 183:3512-3521.
19. Trendelenburg M., Lopez-Trascasa M., Potlukova E., Moll S., Regenass S., Frémeaux-Bacchi V., et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006, 21:3115-3121.
20. Moroni G., Trendelenburg M., Del Papa N., Quaglini S., Raschi E., Panzeri P., et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001, 37:490-498.
21. Petri M., Stohl W., Chatham W., McCune W.J., Chevrier M., Ryel J., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58(8):2453-2459.
22. Hahn B, Singh R. Animal Models of SLE. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus 7th ed.; 2007; p. 299-355.
23. Esdaile J.M., Joseph L., MacKenzie T., Kashgarian M., Hayslett J.P. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994, 21(11):2046-2051.
24. Jacobsen S., Starklint H., Petersen J., Ullman S., Junker P., Voss A., et al. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol 1999, 28(5):288-299.
25. Faurschou M., Starklint H., Halberg P., Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006, 33(8):1563-1569.
26. Ciruelo E., De la Cruz J., López I., Gómez-Reino J.J. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996, 39(12):2028-2034.
27. James J.A., Kim-Howard X.R., Bruner B.F., Jonsson M.K., McClain M.T., Arbuckle M.R., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007, 16(6):401-409.
28. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008, 4(8):404-412.
29. Amital H., Szekanecz Z., Szücs G., Dankó K., Nagy E., Csépány T., et al. Serum concentrations of 25-OH Vitamin D in SLE patients are inversely related to disease activity-is it time to routinely supplement SLE patients with vitamin D?. Ann Rheum Dis 2010, 69(6):1155-1157.
30. Dunn S.E., Youssef S., Goldstein M.J., Prod'homme T., Weber M.S., Zamvil S.S., et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006, 203:401-412.
31. Zhang X., Jin J., Peng X., Ramgolam V.S., Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17- regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4- lymphocytes. J Immunol 2008, 180:6988-6996.
32. Amuro H., Ito T., Miyamoto R., Sugimoto H., Torii Y., Son Y., et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 2010, 62(7):2073-2085.
33. Jury E.C., Isenberg D.A., Mauri C., Ehrenstein M.R. Atorvastatin restores Lck expression in T cells from patients with systemic lupus erythematosus and lipid raft-associated. J Immunol 2006, 177:7416-7422.
34. Graham K.L., Lee L.Y., Higgins J.P., Steinman L., Utz P.J., Ho P.P. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum 2008, 58(7):2098-2104.
35. Lawman S., Mauri C., Jury E.C., Cook H.T., Ehrenstein M.R. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004, 173:7641-7646.
36. Bianchi S., Bigazzi R., Caiazza A., Campese V.M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003, 41:565-570.
37. Singh R.P., Hahn B.H., La Cava A. Tuning immune suppression in systemic autoimmunity with self-derived peptides. Inflamm Allergy Drug Targets 2008, 7(4):253-259.
38. Kang H.K., Michaels M.A., Berner B.R., Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005, 174:3247-3255.
39. Hahn B.H., Anderson M., Le E., La Cava A. Anti-DNA Ig peptides promote Treg cell activity in sistemic lupus erythematosus patients. Arthritis Rheum 2008, 58:2488-2497.
40. Sthoeger Z.M., Sharabi A., Molad Y., Asher I., Zinger H., Dayan M., et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 2009, 33:77-82.